Literature DB >> 2082157

Reduced antibody response to the repetitive sequence of the Plasmodium falciparum circumsporozoite protein in mice infected with Plasmodium yoelii blood forms.

D Grillot1, A Pessi, A S Verdini, P H Lambert, G Del Giudice.   

Abstract

The immunogenicity of the carrier-free synthetic peptide, (NANP)40, from the repetitive region of the Plasmodium falciparum circumsporozoite (CS) protein was investigated in genetically responder mice (C57BL/6, H-2b) acutely infected with blood forms of the non-lethal murine malaria parasite, P. yoelii. As compared to non-infected mice, P. yoelii-infected C57BL/6 mice produced significantly lower titers of anti-(NANP)40 IgG antibodies. This decrease in the anti-(NANP)40 antibody response peaked with the peak of parasitemia, and involved all the IgG subclasses. Interestingly, this P. yoelii-mediated effect was evident both on the development of the antibody response to the (NANP)40 peptide, and on an already established anti-(NANP)40 antibody titer, as seen in mice immunized with the peptide 1 month before the infection. Since (NANP)n-based constructs are strongly envisaged as potential vaccines against falciparum malaria, these results might be important in the evaluation of the efficacy of these vaccine candidates, when they will be used in individuals living in endemic areas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2082157     DOI: 10.1007/BF00192461

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  34 in total

1.  Interleukin-2 reverses T cell unresponsiveness to Plasmodium falciparum-antigen in malaria immune subjects.

Authors:  C Chizzolini; A Geinoz; D Schrijvers
Journal:  Cell Immunol       Date:  1990-06       Impact factor: 4.868

2.  Depression of immune response to Moloney leukaemia virus by malarial infection.

Authors:  R Bomford; N Wedderburn
Journal:  Nature       Date:  1973-04-13       Impact factor: 49.962

3.  Immunosuppression in children with malaria.

Authors:  B M Greenwood; A M Bradley-Moore; A D Bryceson; A Palit
Journal:  Lancet       Date:  1972-01-22       Impact factor: 79.321

4.  Malarial immunodepression in vitro: adherent spleen cells are functionally defective as accessory cells in the response to horse erythrocytes.

Authors:  H S Warren; W P Weidanz
Journal:  Eur J Immunol       Date:  1976-11       Impact factor: 5.532

5.  T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria.

Authors:  H C Whittle; J Brown; K Marsh; B M Greenwood; P Seidelin; H Tighe; L Wedderburn
Journal:  Nature       Date:  1984 Nov 29-Dec 5       Impact factor: 49.962

6.  Inhibition of the immune response to pertussis vaccine during Plasmodium berghei yoelii infection in mice.

Authors:  P Viens; A Tarzaali; M Quevillon
Journal:  Am J Trop Med Hyg       Date:  1974-09       Impact factor: 2.345

7.  Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum.

Authors:  H M Etlinger; A M Felix; D Gillessen; E P Heimer; M Just; J R Pink; F Sinigaglia; D Stürchler; B Takacs; A Trzeciak
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

8.  Antigen-specific immunosuppression in human malaria due to Plasmodium falciparum.

Authors:  M Ho; H K Webster; S Looareesuwan; W Supanaranond; R E Phillips; P Chanthavanich; D A Warrell
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

9.  Immunosuppression in murine malaria. I. Response to type III pneumococcal polysaccharide.

Authors:  J S McBride; H S Micklem; J M Ure
Journal:  Immunology       Date:  1977-05       Impact factor: 7.397

10.  Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine.

Authors:  M F Good; J A Berzofsky; W L Maloy; Y Hayashi; N Fujii; W T Hockmeyer; L H Miller
Journal:  J Exp Med       Date:  1986-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.